Cyclacel Pharmaceuticals (United States)
- Research works
- 4 ▲ 312% vs 2013–17
- Citations
- 11 3.1 per fractional work
- Top-10% rate
- 5.4% record average 16.5%
- Open access
- 43% world 28%
Not ranked overall: Cyclacel Pharmaceuticals (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Which research topics does Cyclacel Pharmaceuticals (United States) publish most on?
By volume in 2022–2025: Chronic Lymphocytic Leukemia Research, T-cell and Retrovirus Studies, Advanced Breast Cancer Therapies and Lung Cancer Research Studies.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Chronic Lymphocytic Leukemia Research Genetics 0 works
- 2 T-cell and Retrovirus Studies Immunology 0 works
- 3 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 0 works
- 4 Lung Cancer Research Studies Oncology 0 works
- 5 Neuroendocrine Tumor Research Advances Epidemiology 0 works
- 6 Cancer-related Molecular Pathways Oncology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Cyclacel Pharmaceuticals (United States)'s research output changed?
Output in 2018–2022 was 312% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Berkeley Heights
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.